Literature DB >> 18473765

Cytokines: from gut inflammation to colorectal cancer.

Massimo C Fantini1, Francesco Pallone.   

Abstract

Colorectal cancer represents a life-threatening complication of inflammatory bowel diseases. Statistics indicate that the risk to develop colorectal cancer is higher in patients affected by ulcerative colitis and to a lesser extent by Crohn's disease and that such a risk is directly proportional to the number of years of active disease. These observations suggest that chronic inflammation may substantially contribute to cancer development. However the molecular mechanisms underlying this process have been only recently started to be clarified. Indeed from the initial concept that the release of free radicals during inflammation might induce the accumulation of genetic mutations thus leading to the onset of dysplastic cells, it is now becoming clear that the large amount of cytokines and growth factors released during inflammation by immune and non immune cells may influence the carcinogenesis process. IL-6 and IL-23, cytokines which play key roles in the induction and maintenance of gut inflammation during IBDs, have been recently shown to influence the development and growth of colitis associated colorectal cancer. Moreover, the activation of the nuclear factor kappa B (NF kappa B), a transcription factor activated by several cytokines released during inflammation and responsible for many of their proinflammatory effects, have been shown to promote the growth of the colon tumors in experimental models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473765     DOI: 10.2174/138945008784221206

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  58 in total

1.  Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.

Authors:  Martha L Slattery; Abbie Lundgreen; Jennifer S Herrick; Roger K Wolff
Journal:  Mutat Res       Date:  2010-10-28       Impact factor: 2.433

Review 2.  Is HCMV a tumor promoter?

Authors:  Liliana Soroceanu; Charles S Cobbs
Journal:  Virus Res       Date:  2010-10-29       Impact factor: 3.303

Review 3.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

4.  Role of Lymphatic Deficiency in the Pathogenesis and Progression of Inflammatory Bowel Disease to Colorectal Cancer in an Experimental Mouse Model.

Authors:  Sarah K Daley; Marlys H Witte; Jalicia Washington; Michael Bernas; Pawel Kiela; Jennifer Thorn; Nathan Tanoue; J Steven Alexander
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

Review 5.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

6.  Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin.

Authors:  Subapriya Rajamanickam; Balaiya Velmurugan; Manjinder Kaur; Rana P Singh; Rajesh Agarwal
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

7.  Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy.

Authors:  Yue Zhao; Qinglong Guo; Kai Zhao; Yuxin Zhou; Wenjun Li; Chuyue Pan; Lei Qiang; Zhiyu Li; Na Lu
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

8.  GM-CSF facilitates the development of inflammation-associated colorectal carcinoma.

Authors:  Guojiang Chen; Gencheng Han; Beifen Shen; Yan Li
Journal:  Oncoimmunology       Date:  2014-03-07       Impact factor: 8.110

9.  Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice.

Authors:  Ibrahim Altamemi; E Angela Murphy; James F Catroppo; Elizabeth E Zumbrun; Jiajia Zhang; Jamie L McClellan; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

10.  IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry.

Authors:  Brenna L Seufert; Elizabeth M Poole; John Whitton; Liren Xiao; Karen W Makar; Peter T Campbell; Richard J Kulmacz; John A Baron; Polly A Newcomb; Martha L Slattery; John D Potter; Cornelia M Ulrich
Journal:  Carcinogenesis       Date:  2012-09-22       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.